GSK Shares Fall 7% After Shingrix Sales Disappoint
GSK reported lower-than-expected sales for its bestselling shingles vaccine, Shingrix, mainly due to weakness in China. Shares fell 7% in European midday trading Wednesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.